An interventional study of Structured Pacing and Usual Care in Long COVID, Long Covid19 and Long Covid-19, sponsored by Duke University. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.
Sponsored by Duke University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 195 studies in Post-Acute COVID-19 Syndrome with a site in United States — 63 open to participants now, 85 under way, 7 of them phase 3. Post-Acute COVID-19 Syndrome · United States.
Among the 195 studies in Post-Acute COVID-19 Syndrome with a site in United States, this one is the 22nd largest by enrollment of the 156 interventional ones that give a count, is one of 43 that started in 2024, is one of 78 with no phase, and was the 134th registered.
606 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.
Browse Post-Acute COVID-19 Syndrome studies →63 of the 195 studies in Post-Acute COVID-19 Syndrome with a site in United States are open now. Recruiting first, the newest first:
University of North Carolina, Chapel Hill · Sites in United States
Ages 18–75
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 18–65
Massachusetts General Hospital · Sites in United States
Ages 18–65
University of California, San Francisco · Sites in United States
Ages 18+ · Healthy volunteers
VA Office of Research and Development · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 144 Post-Acute COVID-19 Syndrome studies recruiting now, 69 (48%) set no upper age limit and 53 (37%) stop at 75 or younger; 15 take children under 18; 39 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
195 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 54 · Phase 3 13 · Phase 4 4
First in 2020; this study’s year is marked. 43 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 300 is above the median of 60 across 417 interventional studies indexed under Post-Acute COVID-19 Syndrome.
Median enrollment 53 across the 156 interventional studies, 155 across the 37 observational. Of the 96 that completed or were terminated, 30 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 195 have an industry lead sponsor. The 10 most frequent:
Duke University is the lead sponsor of 2,064 studies on the registry; 271 are open to participants now.
Of its 204 completed or terminated interventional studies of FDA-regulated products, 170 (83%) have results posted.
Duke University has 8 studies filed under Post-Acute COVID-19 Syndrome — fewer than ten, so there is no comparison to draw.
30 of the studies in Post-Acute COVID-19 Syndrome with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04948203Phase 3University of ChicagoAssessing the Efficacy of Sirolimus in Patients With COVID-19 Pneumonia for Prevention of Post-COVID Fibrosis | 2026-12 |
| NCT06928272Phase 3Douglas D. FraserLong Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study | 2026-12 |
| NCT06974084Phase 3HealthBio, Inc.A Multi-Center, Individually-Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Superiority Trial to Evaluate the Efficacy of the Combination of Maraviroc and Atorvastatin for the Treatment of Subjects With Long COVID | 2026-12-01 |
| NCT06960928Phase 3Icahn School of Medicine at Mount SinaiLow Dose Sirolimus in People With Post-Acute Sequelae of COVID-19 (PASC) Long COVID-19 | 2026-12-31 |
| NCT06511063Icahn School of Medicine at Mount SinaiAntiviral Clinical Trial for Long Covid-19 | 2026-11 |
Add all 30 to your calendar (.ics) → With an account.
Among the 195 studies in Post-Acute COVID-19 Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a platform protocol designed to be flexible so that it is suitable for a range of interventions and settings within diverse health care systems and community settings with incorporation into clinical COVID-19 management programs and treatment plans if results achieve key study outcomes.
This protocol is a prospective, multi-center, multi-arm, randomized, controlled platform trial evaluating interventions to address and improve exercise intolerance and post-exertional malaise (PEM) as manifestations of Post-Acute Sequelae of SARS-CoV-2 Infection (PASC).
The focus of this protocol is to assess interventions that can improve exercise capacity, daily activities tolerance, and quality of life in patients with PASC.
Study interventions will be added to the platform protocol as appendices. Each appendix will leverage all elements of the platform protocol, with additional elements described in the individual appendix. Study intervention appendices may be added or removed according to adaptive design and/or emerging evidence.
The platform protocol enrolls participants who meet study eligibility criteria. After completing initial screening assessments, eligible participants are assigned to one of the study intervention appendices that are actively enrolling. Participants must meet certain criteria within a specific appendix in order to be included in that appendix. Once assigned to an appendix, eligible participants are randomized to either the study intervention group or a control group.
Additional Appendix B (Structured Pacing (PEM)) Level Inclusion Criteria:
or Score of 3 or greater on any severity question(regardless) and answer of YES to either item 7 or 8 on the Screening mDSQ-PEM, and response of >14h in item 9.
Additional Appendix B (Structured Pacing (PEM)) Level Exclusion Criteria:
Participants in this group will complete weekly pacing sessions for 12 weeks. Pacing sessions will last about 30 minutes, as tolerated. Each participant will meet with a provider 'pacing coach' who has received study-specific education about PEM and how to create and manage pacing strategies for participants. Sessions include PEM symptom and trigger assessment; task, function and activity analysis; adaptations and modifications.
Behavioral: Structured Pacing
Participants in this group will receive basic education about PEM with a weekly call by site study staff for support and communication.
Other: Usual Care
Participants in this group will complete weekly pacing sessions for 12 weeks. Pacing sessions will last about 30 minutes, as tolerated. Each participant will meet with a provider 'pacing coach' who has received study-specific education about PEM and how to create and manage pacing strategies for participants. Sessions include PEM symptom and trigger assessment; task, function and activity analysis; adaptations and modifications.
Participants in this group will receive basic education about PEM with a weekly call by site study staff for support and communication.
Change in Frequency of PEM Symptoms, as Measured by the Modified DePaul Symptom - Post-Exertional Malaise Questionnaire (mDSQ-PEM)
Symptom frequency is rated on a 5-point Likert scale: 0 = none of the time, 1 = a little of the time, 2 = about half the time, 3 = most of the time, and 4 = all of the time.
Time frame: Baseline, week 12 (End Of Intervention, EOI)
Change in Severity of PEM Symptoms, as Measured by the Modified DePaul Symptom - Post-Exertional Malaise Questionnaire (mDSQ-PEM)
Symptom severity is rated on a 5-point Likert scale: 0 = symptom not present, 1 = mild, 2 = moderate, 3 = severe, 4 = very severe.
Time frame: Baseline, week 12 (EOI)
Change in Duration of PEM Symptoms, as Measured by the Modified DePaul Symptom - Post-Exertional Malaise Questionnaire (mDSQ-PEM)
Ordinal categorical response: \<=1 hour, 2-3 hours, 4-10 hours, 11-13 hours, 14-23 hours, \>=24 hours. Reported as the number of participants who provided each response.
Time frame: Baseline, week 12 (EOI)
Change in PASC Symptoms, as Measured by the PROMIS-Cog Questionnaire
The PROMIS Short Form v.2.0 - Cognitive Function 8a (PROMIS-Cog) is the PROMIS Short Form to assess cognitive function and is a self-report, 8-item questionnaire targeting cognitive function in the past seven days. T-Scores in a healthy reference population have mean=50 and standard deviation = 10, with higher scores indicating higher functioning.
Time frame: Baseline, week 6 (Middle of Intervention), week 12 (EOI), month 6 (EOS)
Change in Quality of Life, as Measured by the PROMIS-29+2
The PROMIS-29+2 is used to calculate a preference score (PROPr) by the addition of two Cognitive Function Ability items. Preference-based scores provide an overall summary of health-related quality of life on a common metric. Preference-based scores summarize multiple domains on a metric ranging from 0 (as bad as dead) to 1 (perfect or ideal health).
Time frame: Baseline, week 6 (Middle of Intervention), week 12 (EOI), month 6 (EOS)
Change in Quality of Life, as Measured by the EQ-5D 5L
The EQ-5D is a standardized measure of health status. Mobility was measured on a scale from 1 (no problems in walking) to 5 (unable to walk).
Time frame: Baseline, week 6 (Middle of Intervention), week 12 (EOI), month 6 (EOS)
Change in Step Count (Physical Activity) as Measured by Actigraphy
Actigraphy will be measured by Fitbit. Participant steps were considered valid from days where they wore the Fitbit at least 10 waking hours. Average steps were calculated from subjects with at least 5 consecutive days of valid data within a week window of their expected visit dates.
Time frame: Baseline, week 6 (Middle of Intervention), week 12 (EOI), month 6 (EOS)
Change in Physical Activity, as Measured by the PROMIS SF-Physical Function (PROMIS-PF)
The PROMIS Short Form v2.0 - Physical Function 8b (PROMIS-PF) consists of 8 items. The PROMIS Physical Function instruments measure self-reported capability rather than actual performance of physical activities. T-Scores in a healthy reference population have mean = 50 and standard deviation = 10, with higher scores indicating higher functioning.
Time frame: Baseline, week 6 (Middle of Intervention), week 12 (EOI), month 6 (EOS)
Change in Orthostatic Hypotension, as Measured by the Modified Orthostatic Hypotension Questionnaire (mOHQ)
The Orthostatic Hypotension Questionnaire (OHQ) is a measure of orthostatic intolerance. The modified OHQ (mOHQ) measure used in this study includes a total of ten items related to daily activities and symptoms. The OHQ composite score ranges from 0 (no burden) to 10 (maximal burden). Higher scores are worse. The OHQ composite score includes 6 symptom items (OISA) and 4 daily activity items (OIDAS).
Time frame: Screening, week 6 (Middle of Intervention), week 12 (EOI), month 6 (EOS)
Change in PASC Symptoms, as Measured by the PASC Symptom Questionnaire
The PASC Symptom Questionnaire is a 33-question survey for self-reporting multiple PASC-related symptoms across multiple systems.
Time frame: Baseline, week 6 (Middle of Intervention), week 12 (EOI), month 6 (EOS)
| Milestone | Structured Pacing | Usual Care |
|---|---|---|
| Started | 151 | 149 |
| Completed | 145 | 144 |
| Not completed | 6 | 5 |
| Withdrew: Lost to follow-up | 2 | 4 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Withdrew: Ineligible due to mohq score | 1 | 0 |
| Withdrew: Randomized incorrectly | 2 | 1 |
Symptom frequency is rated on a 5-point Likert scale: 0 = none of the time, 1 = a little of the time, 2 = about half the time, 3 = most of the time, and 4 = all of the time.
| score on a scale | Structured Pacing | Usual Care |
|---|---|---|
| Change in Frequency of PEM Symptoms, as Measured by the Modified DePaul Symptom - Post-Exertional Malaise Questionnaire (mDSQ-PEM) | -0.53 ± 1.01 | -0.04 ± 0.75 |
Symptom severity is rated on a 5-point Likert scale: 0 = symptom not present, 1 = mild, 2 = moderate, 3 = severe, 4 = very severe.
| score on a scale | Structured Pacing | Usual Care |
|---|---|---|
| Change in Severity of PEM Symptoms, as Measured by the Modified DePaul Symptom - Post-Exertional Malaise Questionnaire (mDSQ-PEM) | -0.49 ± 0.90 | 0.01 ± 0.73 |
Ordinal categorical response: \<=1 hour, 2-3 hours, 4-10 hours, 11-13 hours, 14-23 hours, \>=24 hours. Reported as the number of participants who provided each response.
| Participants | Structured Pacing | Usual Care |
|---|---|---|
| Baseline — <= 1 hour | 4 | 4 |
| Baseline — 2-3 hours | 6 | 4 |
| Baseline — 4-10 hours | 11 | 9 |
| Baseline — 11-13 hours | 4 | 9 |
| Baseline — 14-23 hours | 26 | 26 |
| Baseline — >= 24 hours | 97 | 97 |
| EOI — <= 1 hour | 5 | 2 |
| EOI — 2-3 hours | 22 | 6 |
| EOI — 4-10 hours | 9 | 7 |
| EOI — 11-13 hours | 6 | 3 |
| EOI — 14-23 hours | 24 | 42 |
| EOI — >= 24 hours | 75 | 80 |
The PROMIS Short Form v.2.0 - Cognitive Function 8a (PROMIS-Cog) is the PROMIS Short Form to assess cognitive function and is a self-report, 8-item questionnaire targeting cognitive function in the past seven days. T-Scores in a healthy reference population have mean=50 and standard deviation = 10, with higher scores indicating higher functioning.
| T-score | Structured Pacing | Usual Care |
|---|---|---|
| Baseline to MOI | 1.26 ± 6.16 | 1.01 ± 5.50 |
| Baseline to EOI | 3.08 ± 8.44 | 0.68 ± 6.77 |
| Baseline to EOS | 3.02 ± 8.23 | 1.33 ± 5.94 |
The PROMIS-29+2 is used to calculate a preference score (PROPr) by the addition of two Cognitive Function Ability items. Preference-based scores provide an overall summary of health-related quality of life on a common metric. Preference-based scores summarize multiple domains on a metric ranging from 0 (as bad as dead) to 1 (perfect or ideal health).
| score on a scale | Structured Pacing | Usual Care |
|---|---|---|
| Baseline to MOI | 0.03 ± 0.11 | 0.00 ± 0.10 |
| Baseline to EOI | 0.06 ± 0.14 | -0.01 ± 0.11 |
| Baseline to EOS | 0.06 ± 0.14 | 0.01 ± 0.12 |
The EQ-5D is a standardized measure of health status. Mobility was measured on a scale from 1 (no problems in walking) to 5 (unable to walk).
| score on a scale | Structured Pacing | Usual Care |
|---|---|---|
| Baseline to MOI | -0.03 ± 0.83 | 0.09 ± 0.73 |
| Baseline to EOI | -0.06 ± 0.87 | 0.13 ± 0.75 |
| Baseline to EOS | 0.04 ± 0.91 | 0.05 ± 0.72 |
Actigraphy will be measured by Fitbit. Participant steps were considered valid from days where they wore the Fitbit at least 10 waking hours. Average steps were calculated from subjects with at least 5 consecutive days of valid data within a week window of their expected visit dates.
| steps per day | Structured Pacing | Usual Care |
|---|---|---|
| Baseline to MOI | 116.8 ± 1563.7 | 98.03 ± 1784.12 |
| Baseline to EOI | 305.17 ± 2319.07 | 75.42 ± 1810.99 |
| Baseline to EOS | 148.40 ± 2256.0 | -168.64 ± 1725.16 |
The PROMIS Short Form v2.0 - Physical Function 8b (PROMIS-PF) consists of 8 items. The PROMIS Physical Function instruments measure self-reported capability rather than actual performance of physical activities. T-Scores in a healthy reference population have mean = 50 and standard deviation = 10, with higher scores indicating higher functioning.
| T-score | Structured Pacing | Usual Care |
|---|---|---|
| Baseline to MOI | -0.13 ± 3.39 | 0.14 ± 3.13 |
| Baseline to EOI | 1.17 ± 4.19 | 0.31 ± 3.36 |
| Baseline to EOS | 1.35 ± 4.62 | 0.28 ± 3.72 |
The Orthostatic Hypotension Questionnaire (OHQ) is a measure of orthostatic intolerance. The modified OHQ (mOHQ) measure used in this study includes a total of ten items related to daily activities and symptoms. The OHQ composite score ranges from 0 (no burden) to 10 (maximal burden). Higher scores are worse. The OHQ composite score includes 6 symptom items (OISA) and 4 daily activity items (OIDAS).
| score on a scale | Structured Pacing | Usual Care |
|---|---|---|
| Baseline to MOI | -0.91 ± 1.89 | -0.72 ± 1.63 |
| Baseline to EOI | -1.32 ± 2.24 | -0.63 ± 1.70 |
| Baseline to EOS | -1.26 ± 2.34 | -0.84 ± 1.81 |
The PASC Symptom Questionnaire is a 33-question survey for self-reporting multiple PASC-related symptoms across multiple systems.
Results for this outcome have not been posted.
Collected over From first invasive procedure (after consent but before randomization) until end of study, approximately 6 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Structured Pacing | 0/149 (0%) | 6/149 (4%) | 0/149 (0%) |
| Usual Care | 0/149 (0%) | 4/149 (2.7%) | 0/149 (0%) |
| Event | Structured Pacing | Usual Care |
|---|---|---|
| Thrombotic thrombocytopenic purpuraBlood and lymphatic system disorders | 1/149 | 0/149 |
| Atrial fibrillationCardiac disorders | 1/149 | 0/149 |
| Coronary artery stenosisCardiac disorders | 1/149 | 0/149 |
| Coeliac artery stenosisGastrointestinal disorders | 0/149 | 1/149 |
| ConstipationGastrointestinal disorders | 0/149 | 1/149 |
| Catheter site haemorrhageGeneral disorders | 0/149 | 1/149 |
| Cholecystitis acuteHepatobiliary disorders | 0/149 | 1/149 |
| Abdominal wall abscessInfections and infestations | 0/149 | 1/149 |
| CellulitisInfections and infestations | 0/149 | 1/149 |
| Pneumonia influenzalInfections and infestations | 1/149 | 0/149 |
All randomized subjects who received any randomly assigned treatment. Two subjects in the Structured Pacing group did not receive treatment.
| Age, Continuous(years) | Structured Pacing | Usual Care | Total |
|---|---|---|---|
| Median | 50.4 (42.4 to 59.1) | 50.1 (39.2 to 59.5) | 50.4 (40.0 to 59.2) |
| Sex: Female, Male(Participants) | Structured Pacing | Usual Care | Total |
|---|---|---|---|
| Female | 113 | 110 | 223 |
| Male | 36 | 39 | 75 |
| Race/Ethnicity, Customized(Participants) | Structured Pacing | Usual Care | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 2 | 3 | 5 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| Black or African American | 14 | 9 | 23 |
| Middle Eastern or North African | 1 | 0 | 1 |
| White | 125 | 126 | 251 |
| More than one race | 5 | 4 | 9 |
| Unknown or Not Reported | 0 | 7 | 7 |
| Region of Enrollment(Participants) | Structured Pacing | Usual Care | Total |
|---|---|---|---|
| United States | 149 | 149 | 298 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — The summary of the results will be shared on the study website: https://recovercovid.org/
Ran from Jul 2024 to primary completion in Aug 2025, 13 months.
Results were first posted in Oct 2026, 1 year 1 month after primary completion.
Of 232 non-industry interventional studies with no phase under Post-Acute COVID-19 Syndrome, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 28. This study's 13 months is below that.
Counting every sponsor, half of 243 studies reached it within 16 months; a quarter within 7 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Post-Acute COVID-19 Syndrome →